ICH Q7 Compliance for APIs
Manufactured by Cell Culture/Fermentation
Monday - Joint Programme
COMPLIANCE SESSION PART 1 – MANAGEMENT PROCESS
APIC’s "How to do" Guide and further APIC Activities
- Information on APIC
- Contribution to GMP Compliance and Supply Chain Integrity
- How to do Document
- Quality Agreements
- ASMF Guideline
- FMD and GDP for APIs - ICH Q7 Q&A How to do Document
- Further activities
ICH – A General Introduction
- What is ICH?
- API related ICH Guidelines
- ICH Quality Guidelines
- ICH Q7 – Hot topics and requirements
- Overview of guidance documents (Q8 to Q14)
Regulatory Framework - an Inspector’s View
- Overview: relevant guidelines
- Inspections in drug product facilities - relevant topics for API manufacturers
- Recent findings in inspections
Major Compliance Issues at API Manufacturers
- Common pitfalls and typical audit findings
- Top observations from inspections by European authorities
- Experiences made by FDA
- Recent statistics from FDA Warning Letters to API manufacturers
Preparing for GMP Inspections
- Experience with GMP inspections of API manufacturers
- Major findings/observations during inspections
- Survey on frequently asked questions – discussion
Tuesday - Joint Programme
COMPLIANCE SESSION PART 2 – LIFE CYCLE MANAGEMENT AND CONTINUOUS IMPROVEMENT
API in IMP - a Risk Based Approach
- IMP Regulations in ICH Q7: Chapter 19, new WHO drafts on IMPs
- What is different from Commercial Products?
- What is the necessary Degree of Formality?
- What does appropriate means practically?
- Phase-appropriateness: a practical approach to systematic Risk Management in development
Supply Chain Life Cycle: Reduced Testing and Supplier Qualification
- ICH Q7 requirements
- Supplier qualification covering the full supply chain
- One strategy for supplier qualification from non-critical raw material to API
- Requirements and strategy for reduced testing (CoA release) of materials
Internal Change Control Management
- Changes: Good or bad? Forced or voluntary?
- The importance of Change Control
- Scope and general requirements
- Detailed requirements for specific Changes
- Implementation of Changes
ICH Q7 Q&A – What to do and how to do
- Overview about the ICH Q7 Questions and Answers Document
- Some Highlights from the Q&A Document and their interpretation
- Distribution procedures, intercontinental shipments
- Risk assessment and validation
- Complaints and recalls
- Interactive Session
Stability Testing of APIs
- Stability Specification
- Stability Studies
- Stability test methods
- Stress tests
- Packaging
- Guidance on API stability testing
How to implement ICH Q3D
- Regulatory requirements
- „Five steps implementation strategy“
- How to handle CEP updates and new registrations from the perspective of the Marketing Authorisation Holder
Wednesday Morning - Parallel Sessions
GMP Inspections at Biotech Companies
- General inspection principles
- Cell Banks Facility
- Biological Materials and Culture Media
- Fermentation
- Viral removal/inactivation
- Laboratories
- Recent regulatory findings
- Most common FDA audit observations
Instances of Virus Contamination in GMP manufactured Products – what can we learn?
- Virus contamination in GMP manufactured products (examples)
- How to implement continued vigilance with regard to potential virus contamination
- Virus contamination and root cause analysis
- Application of appropriate risk control measures
- Approaches to minimise the risk of contamination
Cellbanking –Master Cell Banks (MCB) and Working Cell Banks (WCB)
- Establishment of MCB and WCB
- Definition of ’API starting material’
- Cell Bank qualification and testing
- Cell Bank maintenance and record keeping
Cleaning and Cleaning Validation in Biotech Manufacturing Processes
- Identification of cleaning mechanisms and selection of cleaning agents
- Selection of analytical methods for the detection of residues
- Establishment of limits in fermentation and downstream processing
- Grouping strategies
- Final rinse versus swab testing